|
Originally published In Press as doi:10.1074/jbc.M204930200 on June 17, 2002
J. Biol. Chem., Vol. 277, Issue 34, 30690-30698, August 23, 2002
Alteration of the C-terminal Amino Acid of Tubulin Specifically
Inhibits Myogenic Differentiation*
Winston
Chang §,
Daniel R.
Webster¶,
Ambar A.
Salam ,
Dorota
Gruber ,
Aparna
Prasad ,
Jason P.
Eiserich , and
J. Chloë
Bulinski §**
From the Departments of Biological Sciences, Anatomy
& Cell Biology, & Pathology, Colleges of Arts & Sciences and Physicians
& Surgeons and the § Integrated Program in Cell, Molecular & Biophysical Studies, Columbia University, New York, New York
10027-2450, the ¶ Department of Cell Biology & Biochemistry, Texas
Tech University, Health Sciences Center, Lubbock, Texas 79430, and
the Department of Internal Medicine, University of
California, Davis, California 95616
Received for publication, May 20, 2002
 |
ABSTRACT |
Detyrosination is an evolutionarily conserved
post-translational modification of microtubule polymers that is known
to be enhanced during early morphological differentiation of cultured myogenic cells (Gundersen, G. G., Khawaja, S., and Bulinski,
J. C. (1989) J. Cell Biol. 109, 2275-2288). We
proposed that altering the C terminus of -tubulin by detyrosination
plays a role in morphological differentiation. To test our hypothesis,
we treated L6 myoblasts with 3-nitrotyrosine (Eiserich, J. P.,
Estevez, A. G., Bamberg, T. V., Ye, Y. Z., Chumley,
P. H., Beckman, J. S., and Freeman, B. A. (1999)
Proc. Natl. Acad. Sci. U. S. A. 96, 6365-6375), a
nontoxic inhibitor that resulted in high level inhibition of
microtubule detyrosination and low level incorporation of nitrotyrosine into microtubules. Even though microtubule stabilization or
modification by acetylation still occurred normally, morphological
differentiation was blocked; myoblasts neither elongated significantly
nor fused. Nitrotyrosine treatment prevented synthesis or activation of
markers of myogenic differentiation, including muscle-specific myosin, -actin, integrin 7, and myogenin. Consistent
with this, myoblast integrin 1A remained highly
expressed. In contrast, the increase in -catenin level
characteristic of early myogenesis was unaffected by treatment. These
results show that the identity of the C-terminal residue of -tubulin
modulates microtubule activity, possibly because binding to or
signaling from modified microtubules is required for the myogenic program.
 |
INTRODUCTION |
Microtubules (MTs)1
participate in cell division, motility, transport, and morphogenesis.
The ability of MTs to quickly polymerize and depolymerize, a process
known as dynamic instability, places regulation of MT dynamics at the
center of active research (1). Tubulin undergoes a host of
post-translational modifications, including detyrosination,
acetylation, generation of 2-tubulin, phosphorylation,
polyglutamylation, and polyglycylation (2). Of these, detyrosination
has been most extensively studied, yet its functions remain to be determined.
Detyrosination is a unique modification involving cleavage of the
C-terminal tyrosine residue of -tubulin within MTs by a tubulin-specific carboxypeptidase (TCP), leaving Glu tubulin, named for
its newly exposed C-terminal residue. Detyrosination is reversible:
tubulin tyrosine ligase (TTL) adds a tyrosine residue to the C terminus
of protomeric Glu-tubulin, re-forming tyrosinated (Tyr) tubulin (2, 3).
MTs enriched in Glu tubulin (called Glu MTs) have been shown to be
enhanced in cellular longevity or stability (4-6). However,
detyrosination is known to be insufficient to stabilize MTs (7, 8),
rendering detyrosination an effect, not a cause, of MT stability.
Glu MTs are found in a distinct subset of MTs in undifferentiated
cultured cells (9). Usually the Glu MT subset largely overlaps with the
subset enriched in post-translationally acetylated subunits (10, 11),
suggesting that post-translationally modified subunits within a stable
MT may function to establish functionally distinct MT populations. For
example, modified MTs may function in cellular morphogenesis or cell
polarization (3). Antibody microinjections suggest that Glu tubulin
subunits anchor vimentin filaments to MTs in migrating 3T3 fibroblasts
(12) and may be involved in directed organelle transport (13, 14).
The hypothesis that stable Glu MTs are involved in cellular
morphogenesis is suggested by their increased abundance during differentiative events (3, 15). However, to date no study has
demonstrated that Glu MTs are necessary for differentiation. During
myogenesis, cells undergo striking morphological changes; they
elongate, align with neighbors, and finally fuse into multinucleated myotubes. In L6 cells, Glu MTs accumulate upon induction of myogenesis, coincident with formation of stable MTs and preceding myoblast fusion,
accumulation of post-translationally acetylated MTs, and appearance of
muscle-specific myosin (16). A test of the functional consequences of
inhibiting MT detyrosination during myogenesis has not been
straightforward, largely because no direct inhibitors of TCP are available.
Eiserich et al. (17) showed that a modified amino acid,
3-nitrotyrosine (NO2Tyr), which is generated by reaction of
tyrosine with nitric oxide-derived species, including nitrogen dioxide (·NO2) and peroxynitrite (ONOO )
(18-20), may act as an indirect inhibitor of TCP. That is,
NO2Tyr can be taken up by cells, where the tyrosinating
enzyme, tubulin tyrosine ligase (TTL), can incorporate it into the C
terminus of Glu tubulin to yield nitrotyrosinated tubulin (21).
Eiserich et al. (17) found that, when NO2Tyr was
incorporated, Glu MTs were decreased, and in vitro studies
with carboxypeptidase A suggested that the nitrotyrosinated MTs might
work by blocking the generation of Glu MTs by TCP. In this study, we
show that NO2Tyr-MTs inhibit TCP; consequently,
NO2Tyr can be used as an indirect inhibitor of MT
detyrosination during differentiation of L6 myoblasts. Perturbation of
Glu MT formation prevents myogenic morphogenesis, and accumulation and
activation of muscle-specific factors, revealing a link between MT
modification and progression of the myogenic program.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Unless noted, tissue culture supplies were from
Invitrogen, and sera were from HyClone, Inc. Other chemicals and
antibodies were from Sigma Chemical Co., immunochemicals were from
Organon Teknika, and 4-methyl-2-nitrophenol was from Aldrich Chemical Co.
Cell Culture and Myogenic Differentiation--
Rat L6 myoblasts
(ATCC), maintained in DMEM with 10% fetal bovine serum, were induced
to differentiate by shifting to DMEM with 2% horse serum
(heat-inactivated, 56 °C, 30 min), and the extent of differentiation
was scored (16). To test media of various pH levels, proliferating
cells were incubated in DMEM with serum, lacking sodium bicarbonate,
containing 30 mM HEPES buffer at each pH. Note that the pH
of each medium refers to the pH of the HEPES buffer added, and may not
reflect the pH maintained in the incubator. The pH of unbuffered
control media was ~7.3.
The pH shift protocol (see Fig. 1B) entailed adding pH 7.0 medium, at 37 °C (i.e. maximum Glu tubulin content, see
Fig.1A) to sub-confluent plates of L6 cells for 10 h to
increase Glu MT level. Plates were rinsed once in cold pH 7.8 medium
and placed at 4 °C for 1 h to depolymerize Glu MTs. Next, cells
were incubated at 37 °C for 12 h at pH 7.8 (i.e.
minimum Glu tubulin content) allowing TTL to re-tyrosinate Glu tubulin
protomers, thus reducing Glu tubulin level significantly. Finally,
differentiation medium was added. 400 µM
NO2Tyr was present in half the plates (+NO2Tyr plates) throughout the experiment, and both control plates and those
with added NO2Tyr underwent the pH shift protocol. To
prevent overgrowth of cultures during the time course,
differentiation-defective cells were killed at 2 days with 18 µM -D-arabinofuranoside, which has been
shown not to interfere with myogenesis (22).
Antibodies--
Antibodies were used at dilutions shown
parenthetically: -catenin, C2206 (1:6000); -sarcomeric actin, 5C5
(1:1500); vimentin, V9 (1:400); desmin, D8281 (1:1000); and acetylated
tubulin, 6-11B-1 (1:1000). MF20 hybridoma against muscle-specific
myosin heavy chain was from the Developmental Studies Hybridoma Bank;
undiluted culture supernatant was used. Anti-NO2Tyr (1:800)
was from Upstate Biotechnology, and anti-myogenin, M-225 (1:100) was
from Santa Cruz Biotechnology. Anti- -tubulin, 3F3 (1:2500), was
generously provided by Dr. J. Lessard (University of Cincinnati) and
anti-integrins 1A (1:1000) and 7A (1:500)
were obtained courtesy of Dr. G. Tarone (University of Torino).
Anti-Glu tubulin, SG (1:6000) was previously described (9).
Immunoblotting, Immunofluorescence, and Northern
Blots--
Preparation of cell lysates, SDS-PAGE, Western blotting,
and immunostaining were described in Chapin and Bulinski (23). For
enhanced chemiluminescence (ECL), blots were blocked with 1% bovine
serum albumin; bound antibodies were detected with SuperSignal chemiluminescent substrate (Pierce). Northern blots were performed exactly as described in Gruber et al. (24), using actin and glyceraldehyde-3-phosphate dehydrogenase probes from Ambion (the latter
for normalization of RNA loads).
Immunofluorescence was performed as described in Gundersen et
al. (16). Antibodies were diluted as follows: anti- -tubulin, 3F3, 1:100; anti-Glu, SG, 1:400; and secondary antibodies, 1:100. Images, captured with an Orca-cooled charge-coupled device camera (Hamamatsu Photonics) equipped with a Uniblitz Shutter (Vincent Associates), and attached to a Nikon Optiphot microscope, were processed with MetaMorph software (Universal Imaging).
In Vitro Assay of Tubulin Carboxypeptidase
Activity--
Preparation of brain TCP,
[14C]tyrosine-labeled MT substrate, and the TCP assay,
were described previously (25, 26). Briefly, [14C]tyrosine-labeled tubulin dimers were self-assembled
in MHM (25 mM MOPS, 25 mM HEPES, pH 7.5, 5 mM MgCl2) for 20 min, stabilized by Taxol (20 µM, 5 min), and centrifuged, all at 37 °C
(436,000 × g, 4 min, Optima TL centrifuge; Beckman
Instruments) to yield a MT substrate pellet. For the first incubation
step, i.e. binding of TCP to MT substrate, the pellet from
the previous step was incubated in MHM (10 min, 37 °C) with 5 volumes of crude brain TCP and 20 µM Taxol (26), and the
mixture was centrifuged as before, except at 25 °C. For the second
incubation step, measuring TCP activity, the pellet from the previous
step was resuspended in MHM (30 min, 37 °C), proteins were
precipitated with 10% trichloroacetic acid (w/v) at 4 °C,
centrifuged (245,000 × g, Optima TL), and radioactivity of trichloroacetic acid-soluble (i.e.
containing [14C]tyrosine cleaved by TCP), and insoluble
fractions were counted.
Nitrotyrosinated MT substrate was prepared by resuspending
[14C]tyrosine MT substrate (above) in 100 mM
Tris, pH 8.2 (alkaline pH to allow tyrosine nitration but no cysteine
oxidation), and incubating with 4 mM tetranitromethane, 4%
ethanol (1 h, 37 °C). [14C]Nitrotyrosinated MTs
(NO2Tyr content, 2 mol/mol tubulin dimer, quantified from
A430 nm), were centrifuged (436,000 × g, 4 min), washed with Tris buffer, centrifuged as
before, and used in the TCP assay above. Release of
[14C]NO2Tyr into the supernatant during the
second incubation was measured.
 |
RESULTS |
Nitrotyrosine (NO2Tyr) Inhibits TCP Activity in
Vitro--
To ascertain the mechanism by which NO2Tyr
inhibits generation of Glu MTs, we assayed its effects on TCP activity
in vitro. MT substrate containing
[14C]tyrosine-labeled -tubulin was first
incubated with TCP preparations to allow binding of enzyme to MT
substrate. TCP·MT substrate complex was then incubated, and
TCP activity was measured as [14C]tyrosine released from
the C terminus of the substrate's -tubulin (Refs. 24 and 26, see
"Experimental Procedures"). We first tested whether free
NO2Tyr affected binding of TCP to MT substrate. Table
I shows that adding
NO2Tyr to the initial incubation of MT substrate with TCP
did not affect TCP activity measured, suggesting that free
NO2Tyr does not inhibit the binding of TCP to the MT substrate.
Next, we added NO2Tyr during the second incubation, which
quantified activity of TCP to generate Glu tubulin. We detected no
difference without and with 1 mM NO2Tyr,
indicating that, at a concentration of 1 mM
(i.e. 2.5 times that used in vivo), free NO2Tyr did not interfere with activity of TCP once it was
bound to MT substrate. However, in samples containing 10 mM
NO2Tyr, 25 times the concentration used in vivo,
we did measure a small but significant (<25%, p < 0.05) decrease in TCP activity (Table I). Because TCP activity was
inhibited only at such high NO2Tyr concentrations, and
TCP·MT substrate binding was not inhibited, it is unlikely that free
NO2Tyr interferes significantly with detyrosination
in vitro or in vivo.
Next, we tested whether nitrotyrosinated MT (NO2Tyr-MT)
substrate (i.e. MTs with incorporated NO2Tyr)
could inhibit detyrosination by TCP. NO2Tyr-MT substrate,
prepared by reacting 14C-labeled MT substrate with
tetranitromethane (see "Experimental Procedures"), inhibited TCP
activity effectively (Table I), and this inhibition was due to
nitrotyrosination, rather than denaturation, of MT substrate, because
activity was unaffected by solvent alone (Table I). The facts that 1)
TCP activity bound to and sedimented with NO2Tyr-MT
substrate (data not shown) and 2) NO2Tyr-MT-bound TCP
cleaved neither 14C-labeled-NO2Tyr nor
14C-labeled Tyr suggested that TCP was effectively
sequestered on NO2Tyr-MTs in the enzyme-substrate mixtures.
One would expect similar inhibition in vivo; that is, TCP
would bind NO2Tyr-MTs tightly and would neither cleave
NO2Tyr from the MTs nor readily dissociate to cleave other
Tyr-MTs in the cell. In addition, these results predict that the
species inhibiting TCP in vivo would be
NO2Tyr-MTs rather than free NO2Tyr.
NO2Tyr Specifically Inhibits MT Detyrosination in
Vivo--
A suitable in vivo detyrosination inhibitor must
satisfy three criteria: First, the inhibitor must be nontoxic to L6
cells during the experimental time course. Second, incorporation must be efficient enough either to block -tubulin detyrosination
completely or to prevent increased detyrosination during myogenesis.
Third, the compound has to be incorporated only post-translationally and only into -tubulin. Although all three criteria were met for use
of NO2Tyr in undifferentiated cells (17), satisfying these
criteria in differentiating cells demanded further efforts.
For the first criterion, we examined possible toxicity by incubating
either proliferating or differentiated L6 cells with NO2Tyr
in culture medium for 10 days. No detectable effects on mitosis or
other deleterious effects such as cell death were observed (data not
shown), and proliferation and/or differentiation rates were nearly
normal ( 90% of controls; data not shown).
The second criterion, achieving efficient incorporation of the
inhibitor, posed a significant challenge. Merely incubating L6 cells
for 7 days in culture medium with 400 µM or even 800 µM NO2Tyr did not result in diminution of Glu
tubulin level, or incorporation of NO2Tyr, as detected with
Glu or NO2Tyr antibodies, respectively (data not shown).
The inefficiency of NO2Tyr to perturb detyrosination was
not surprising, because proliferating mammalian cells possess highly
dynamic MTs (10), Glu MTs compose only a small subset (<5%), and Glu
tubulin resides exclusively in polymer (5, 23), where it is unavailable
to TTL. Thus, in proliferating cells <5% of the tubulin is available
for detyrosination and subsequent re-tyrosination by TTL. To prevent
the ~20-fold increase in Glu MTs during myogenesis, we had to improve
NO2Tyr incorporation into MTs and, thus, inhibition of TCP
before inducing differentiation.
One strategy for effecting increased NO2Tyr incorporation
would be to perturb in vivo MT dynamics in
NO2Tyr-containing culture medium, allowing TTL to
incorporate NO2Tyr, in lieu of tyrosine, into Glu protomers
(21). For example, transiently stabilizing MTs would generate Glu MTs
(5); destabilizing these Glu MTs in the presence of NO2Tyr
would release Glu tubulin protomers that could be nitrotyrosinated by
TTL.
We initially attempted to develop a MT stabilization-destabilization
protocol using Taxol to stabilize MTs (5); however, Taxol treatments
proved irreversible. Instead, we explored using pH to influence MT
stability, based on reports that pH affects MT polymerization in
vivo (27). As shown in Fig.
1A, lower
extracellular pH enhanced detyrosination, reaching a maximum Glu
tubulin level at pH 7.0. Glu tubulin level was lower at media pH levels
of 7.2-7.5 and was not detected at media pH 7.6-8.0 (Fig.
1A). Overexposure of blots revealed a nadir in Glu tubulin
level at pH 7.8 (data not shown). Staining of blots with
anti-acetylated tubulin, a standard indicator of stable MTs (10),
suggested that changes in Glu tubulin level were correlated with
changes in MT stability (data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Enhanced incorporation of NO2Tyr
into cellular MTs. A, Glu tubulin level of L6 myoblasts
can be manipulated by altering extracellular pH. Proliferating L6
myoblasts, grown to half confluency in bicarbonate-buffered medium at
pH 7.3, were incubated (10-12 h) in bicarbonate-free media containing
30 mM HEPES at each pH level. Cells reached steady-state
Glu tubulin levels after 10 h of incubation at each pH (not shown).
Cell extracts (30 µg) were blotted, and detyrosinated (Glu
tubulin) and tubulin were immunolabeled. Note that, while Glu
tubulin content varied, total tubulin ( -tubulin) was constant at all
pH levels. B, pH shift protocol promotes efficient
incorporation of NO2Tyr into L6 myoblasts. To maximize
NO2Tyr incorporation into MTs, L6 cells were subjected to a
pH shift protocol, as depicted (see "Experimental Procedures" for
details). The pH shift scheme was carried out with or without
NO2Tyr; only the +NO2Tyr version is shown.
First, the level of cellular Glu MTs was raised by exposure to medium
buffered at pH 7.0, an MT-stabilizing pH that increases Glu MTs
(A), then cells were chilled to depolymerize the resulting
Glu MTs. This releases Glu tubulin protomer, which is a substrate for
TTL. Next, cells were re-warmed and incubated in medium buffered at pH
7.8, an MT-destabilizing pH (Fig. 1A) at which Glu tubulin
content reaches its nadir. Subsequently, cells were re-equilibrated in
unbuffered medium and used immediately in differentiation experiments.
C, NO2Tyr is incorporated into tubulin
efficiently, following the pH shift protocol. L6 cell extract (60 µg)
was immunoblotted with anti-NO2Tyr antibody (a
and b), and anti- -tubulin antibody (a' and
b'). Lanes a and b are from cells that
were (+) and were not ( ) subjected to the pH shift protocol, which
increases NO2Tyr incorporation (compare a and
b) but does not alter tubulin content (compare a'
and b'). D, NO2Tyr is incorporated
specifically into tubulin. Differentiated L6 cell extract (60 µg) was
blotted and immunolabeled with a, anti-NO2Tyr
antibody, and overexposed via ECL. b shows anti-tubulin
immunolabeling of the same lane. Note in lane a that no
nontubulin bands incorporated detectable NO2Tyr. From
densitometric scanning we conclude that >99% of NO2Tyr
was incorporated into tubulin, because even a species that incorporated
1% as much NO2Tyr would have been detected.
|
|
Fig. 1B shows the pH shift protocol devised from these data,
which satisfied the second criterion for use of NO2Tyr,
that is, maximizing its incorporation into -tubulin. Briefly, we
first exposed L6 cell cultures to pH 7.0 medium for 10-12 h to
stabilize MTs and increase Glu MT level. We then cold-treated the cells and incubated them in pH 7.8 medium for 12 h to destabilize MTs. Finally, we applied differentiation medium to start myogenesis. With or
without added NO2Tyr, all cells underwent the pH shift protocol, which markedly improved NO2Tyr incorporation
(Fig. 1C, lane a), compared with simply
incubating cells in NO2Tyr (Fig. 1C, lane
b). In fact, densitometry of anti-NO2Tyr-labeled blots revealed >8-fold more NO2Tyr incorporation in lane
a than in lane b. Moreover, other means of
reversibly stabilizing MTs, e.g. transient sodium azide
treatment, also increased NO2Tyr incorporation into tubulin, and myogenesis was altered identically (data not shown).
The third criterion, that the inhibitor must be incorporated strictly
post-translationally, and only into -tubulin, was met in nonmuscle
cells (17). Likewise, in L6 cells we could not detect translational
incorporation of NO2Tyr. However, concerned that the
slightly slower cell growth rate (<10%) we observed in NO2Tyr-treated versus control cells could result
from translational incorporation of NO2Tyr, albeit at a
level not detectable even on the most sensitive Western blots
(e.g. Fig. 1D), we treated cultures with an
identical concentration (400 µM) of
2-nitro-p-cresyl (4-methyl-2-nitrophenol).
This deaminated/decarboxylated version of NO2Tyr can
neither be used in protein synthesis nor serve as a TTL substrate, and
it was similarly nontoxic; we observed no mitotic defects or apoptosis.
2-Nitro-p-cresyl treatment yielded the same paltry
inhibition of cell growth rate (<10%) as other nitrated phenol
compounds that are incapable of translational incorporation (28). Thus,
NO2Tyr appears to be incorporated only
post-translationally.
Exposing L6 cells to transient pH shifts in the continuous presence of
NO2Tyr yielded incorporation only into -tubulin; even the most sensitive Western blots revealed no other
NO2Tyr-labeled species (Fig. 1D). We also noted
that the severity of NO2Tyr effects on cell
differentiation (see below) was strictly dependent upon the efficiency
of NO2Tyr incorporation into tubulin. For example, proliferating or differentiated myoblasts or mature myotubes were all
unaffected by a 10-day incubation with NO2Tyr if they were not first subjected to the pH shift protocol, and little
NO2Tyr incorporation could be detected in cells that were
NO2Tyr-treated without pH shift (Fig. 1C,
lane b). The pH shift procedure changes MT dynamics (Fig.
1B), heightening the incorporation of NO2Tyr by
TTL into protomeric Glu tubulin; however, it is unlikely that changing
the dynamics of MTs would change incorporation of NO2Tyr into nontubulin proteins. Taken together, these data strongly suggest
that in our experiments NO2Tyr was added only
post-translationally and only to -tubulin.
NO2Tyr Inhibits Detyrosination, but Not MT
Stabilization, during Myogenesis--
To inhibit Glu MT formation
during myogenesis, we first subjected L6 myoblasts to the pH shift
protocol and then placed them in differentiation medium and monitored
their myogenesis for a 10-day period. Fig.
2 documents the depletion of
myogenesis-induced detyrosination. Note that a high level of Glu
tubulin persisted throughout the pre-treatments with cold and pH 7.8, such that the Glu tubulin level was still elevated and
NO2Tyr incorporation was undetectable at the time
differentiation was induced (Fig. 2, lanes marked 0).
However, by the 2-day time point, NO2Tyr incorporation could easily be detected and Glu tubulin level was greatly diminished (Fig. 2, lanes marked 2). Fig. 2 shows that
NO2Tyr dramatically reduced Glu tubulin level
(NO2Tyr lanes). In contrast, Glu tubulin
was abundant in control cells (Fig. 2, C lanes) or cells
exposed to NO2Tyr without prior pH shift (not shown). With or without NO2Tyr, cells commencing differentiation (Fig.
2, 0 lanes) often contained a high Glu tubulin level, albeit
markedly reduced in NO2Tyr-treated cells.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 2.
NO2Tyr incorporation
reduces detyrosination but not acetylation. Extracts of pH-shifted
L6 cells (see "Experimental Procedures") without (control
lanes, C) or with NO2Tyr
(NO2Tyr lanes) and placed in
differentiation medium for 0-10 days were blotted to reveal
NO2Tyr, Glu-tubulin, acetylated tubulin
(Ac-tubulin), and total tubulin ( -tubulin). A
hapten antibody against NO2Tyr was used to visualize all
proteins with covalently incorporated NO2Tyr. As shown in
Fig. 1C for a single time point, no proteins other than
-tubulin were labeled with anti-NO2Tyr. The quantities
of total protein loaded to detect each antigen were:
NO2Tyr, 60 µg; Glu-, Ac-, and -tubulin, 30 µg.
|
|
Although NO2Tyr treatment markedly decreased Glu tubulin
level for the first week of differentiation, the level of Glu tubulin increased during the time course, such that its level was similar in
cells with or without NO2Tyr at the 10-day time point (Fig. 2, 10 lanes, compare C and
NO2Tyr). Eventual failure of the
inhibitor could arise in one or both of two ways: First, even optimal
incorporation efficiency would not result in nitrotyrosination of all
tubulin molecules. Remaining Tyr tubulin, polymerized into Tyr MTs,
could be detyrosinated during the differentiation time course. Second,
Tyr tubulin synthesized and polymerized into Tyr MTs during the 10 days
could also be detyrosinated.
Detyrosination is a post-polymerization modification (5); Glu MTs that
appear during myogenesis in L6 cells represent a stable MT population,
compared with their dynamic Tyr MT counterparts (16). We used
antibodies specific for another modification enriched in stable MTs,
acetylated -tubulin (29), a standard indicator of stable MTs (10),
to ask whether NO2Tyr treatment not only decreased Glu
content but also stability of MTs during differentiation. Fig. 2
shows that acetylation increased equivalently during differentiation, regardless of NO2Tyr treatment, suggesting that MTs were
stabilized normally in NO2Tyr-treated cells, despite the
reduction in Glu tubulin level.
NO2Tyr Inhibits Glu MT Accumulation and Myogenic
Morphogenesis--
L6 cells treated with NO2Tyr for up to
10 days did not differentiate, unlike untreated cells (Fig.
3A) or cells
treated with NO2Tyr without prior pH shift (not pictured).
The low magnification micrographs in Fig. 3A show that,
initially, with or without NO2Tyr treatment, L6 myoblasts
were largely unpolarized, and many mitotic cells were seen (Fig.
3A, panels a and b). At 2 days,
untreated L6 cells had elongated and begun to align with one another
(Fig. 3A, panel c, arrows), although
little fusion had yet occurred. In contrast, few
NO2Tyr-treated cells had become polarized, even fewer
appeared to be aligned with one another (Fig. 3A,
panel d, arrow), and none had fused (Fig.
3A, panel d). After 6 days and 10 days of
differentiation, untreated L6 cells had formed long, compact myotubes
that were often branched tubes. Many contained as many as 100 nuclei.
In contrast, NO2Tyr-treated cells were well-spread and
unpolarized; they had not changed in morphology significantly during
the time course (Fig. 3A, compare panels e and
g to f and h). We quantified the
extent of myogenic differentiation by scoring the percentage of fused
cells (Table II). In control cultures at
10 days, a majority of cells (60%) had fused with their
neighbors, whereas in NO2Tyr-treated cultures fusion was insignificant at any time point (~5%, not statistically different from undifferentiated control cells).

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 3.
A, NO2Tyr treatment blocks
early morphogenetic events of myogenesis. L6 cells were pH shifted
without (a, c, e, and g) or
with NO2Tyr (b, d, f, and
h), allowed to differentiate for 0-10 days, and
photographed under phase illumination. Note the paucity of cells
elongated and aligned parallel to one another in
NO2Tyr-treated, compared with control cells at 2 days
(arrows, d and c). Note that 6 days
and 10 days after induction of differentiation, myoblasts had fused to
form highly developed, multinucleated myotubes in control samples
(e and g), whereas in NO2Tyr-treated
cells morphological differentiation was perturbed; that is, no fusion
was observed. Note the flat, highly spread single cells (f
and h), in contrast to the narrow myotubes (e and
g). Bar in h, 100 µm for all panels.
B, NO2Tyr treatment blocks elaboration of Glu
MTs during myogenesis. L6 cells were pH shifted without (control:
a, d, g, and j) or with
NO2Tyr (b, c, e,
f, h, i, k, and
l), differentiated for 0-10 days, and immunostained to
visualize Glu-enriched MTs (Glu tubulin: a, b,
d, e, g, h, j,
and k) or total tubulin ( -tubulin: c,
f, i, and l). At 0 days, Glu MTs were
abundant in control (a) but less so in
NO2Tyr-treated (b) cells. Although Glu MTs
increased in abundance and staining intensity from 2-10 days in
controls (d, g, and j), little
staining was seen in NO2Tyr-treated cells (e,
h, and k). In contrast, the total MT array was
unaffected by NO2Tyr treatment ( -tub:
c, f, i, and l). Note that
staining intensity with anti-Glu tubulin antibody here correlates with
Western blots (Fig. 2). Arrows indicate a few Glu MTs
visible in NO2Tyr-treated cells at 2, 6, and 10 days
(e, h, and k). Bar in
l, 20 µm.
|
|
We used immunofluorescence to monitor Glu MT distribution during
myogenesis. Before differentiation, both NO2Tyr-treated and untreated cells contained a significant number of Glu MTs (Fig. 3B, panels a-c), but these were fewer in number
and dimmer in NO2Tyr-treated than in control cells (Fig.
3B, panels a and b). Glu MTs in
undifferentiated cells were frequently curly, and they clustered nearby
or circumscribed the nucleus. By 2 days of myogenesis, Glu MTs in
untreated cells had begun to form small, straight bundles aligned
parallel to the long axis of the cell (Fig. 3B,
panel d). At 6 days and 10 days (Fig.
3B, panels g and j), larger bundles of
Glu MTs coursed along the length of highly developed myotubes. In
contrast, at 2 days, NO2Tyr-treated cells contained almost no Glu MTs, and the total MT array was neither aligned nor polarized (Fig. 3B, panels e and f,
respectively). By 6 and 10 days, NO2Tyr-treated cells
showed only a few MTs dimly labeled with Glu antibody (Fig. 3B, panels h and k,
arrows). NO2Tyr treatment did not change the total cellular array of MTs in proliferating cells (not shown) or in
differentiating cells (Fig. 3B, compare panels i
and l to c). Thus, the paucity of Glu MTs
did not stem from a decrease in the total MT array, of which they
represent a subset.
Lack of Glu MTs Blocks Expression of Muscle-specific Structural and
Regulatory Proteins--
As major components of assembling myofibrils,
muscle-specific myosin and sarcomeric -actin are abundantly
expressed at late stages of muscle differentiation, concomitant with
myoblast fusion (30). Because NO2Tyr-treated L6 cells
showed morphological deficits early in myogenesis, we tested whether
these late myogenic markers were properly expressed. As shown in Fig.
4, in control cells, accumulated
muscle-specific myosin increased from a low, basal level in
undifferentiated cells to a high level by 4 days (C lanes). In NO2Tyr-treated cells, myosin expression remained at
basal levels throughout the 10-day time course (Fig. 4,
NO2Tyr lanes). Similarly, sarcomeric
-actin was first detected at 4 days of differentiation in control
cells (Fig. 4, C lanes), whereas it was not detected at any
stage in NO2Tyr-treated cells (Fig. 4, NO2Tyr lanes). From these gene expression
results and those of Fig. 3, which showed NO2Tyr inhibition
of early morphological changes, we conclude that NO2Tyr
treatment prevented both early and later events of myogenesis.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 4.
A, NO2Tyr blocks
accumulation of muscle-specific proteins. Extracts of pH-shifted
L6 cells without (control lanes, C) or with
NO2Tyr, differentiated for 0-10 days, were immunoblotted
with antibodies to muscle-specific myosin heavy chain
(myosin), sarcomeric -actin, vimentin, and myogenin. 60, 60, 65, and 65 µg of extract protein were used to detect each
antigen, respectively. p and h mark the
electrophoretic position of phosphorylated and hypophosphorylated
(active) myogenin, respectively. B, NO2Tyr
treatment does not affect accumulation of muscle-specific actin
transcript. Total RNA (20 µg) from pH-shifted L6 cells without
(control lanes, C) or with NO2Tyr,
differentiated for 0-10 days, were hybridized with a muscle actin
probe (actin lanes) and a glyceraldehyde-3-phosphate
dehydrogenase probe, as a loading control. Notice that
NO2Tyr treatment does not change the muscle actin
transcript level detectably, in contrast to effects of the treatment on
actin protein (compare B and A).
|
|
Fig. 4B shows that actin transcript accumulation, which
precedes accumulation of -actin, was not inhibited by
NO2Tyr treatment, in contrast to the striking inhibition of
accumulation of muscle actin protein. NO2Tyr most likely
inhibits actin expression by inhibiting its translation or its
accumulation, rather than its transcription. Because NO2Tyr
prevents myofibril assembly, actin turnover could conceivably be
affected by its assembly state.
The intermediate filament protein, vimentin, was previously shown to
colocalize with Glu MTs in fibroblasts and to depend upon this MT
subset for extension into peripheral areas of the cell (12). To
determine whether a decrease in Glu MT level affected the level of
vimentin, we probed blots of differentiating L6 cells with
anti-vimentin (Fig. 4). The level of accumulated vimentin remained
constant during differentiation regardless of treatment, indicating
that vimentin level was insensitive to either the increase in Glu MTs
during differentiation (in control cells) or the absence of Glu MTs (in
NO2Tyr-treated cells). This result presents the possibility
that vimentin filaments may not utilize Glu MTs as interaction partners
in muscle cells.
During differentiation of muscle tissue, expression of desmin
intermediate filaments is induced. We hypothesized that desmin, which
is highly homologous to vimentin, might be affected by
NO2Tyr depletion of Glu MTs. However, L6 cells were
reported not to express desmin (31). Consistent with this finding, we
were unable to detect either desmin protein or mRNA on Western or
Northern blots, with or without NO2Tyr treatment.
Our findings, that altering a cytoskeletal protein affected expression
of muscle-specific cytoskeletal proteins, actin and myosin, prompted us
to ask whether expression of a regulatory protein might be similarly
affected. If transcription factors were affected by NO2Tyr,
expression of a subset of muscle-specific genes might then be blocked.
Myogenin is the most relevant transcription factor in our system. Of
the known myogenic basic helix-loop-helix transcription factors, L6
muscle cells express abundant myogenin, a low level of Myf-5, and no
detectable MyoD (32, 33). In addition, myogenin synthesis is known to
up-regulate its expression level, whereas myogenin phosphorylation
negatively regulates its DNA binding activity (34). As shown in Fig. 4,
we were able to assay both active and inactive forms, because myogenin
separates electrophoretically into two bands: the active,
hypophosphorylated form that migrates more rapidly (labeled
h) than the inactive, phosphorylated form (labeled p)
(35-37).
In control cultures (C lanes), myogenin expression was
up-regulated at the onset of myogenesis (Fig. 4, compare 2d
to 0d). Blots revealed that the active, hypophosphorylated
species was more abundant than the phosphorylated species (Fig. 4,
compare h and p bands in lanes C), and
the intensity of both h and p bands increased
during differentiation (C lanes). In contrast,
NO2Tyr treatment lowered the level of the lower molecular
weight h band (i.e. active myogenin), throughout
differentiation, whereas it did not have a consistent effect on the
level of inactive phosphorylated myogenin (Fig. 4,
NO2Tyr lanes, p band). The
finding that NO2Tyr-treated cells possessed less of the
active form of myogenin suggested that Glu MTs are necessary for
synthesis or accumulation of a muscle-specific transcription factor.
Expression of Cell Adhesion Molecules Is Perturbed by
NO2Tyr Treatment--
Because inhibition of Glu MT
formation impacted upon both muscle-specific structural and regulatory
proteins, as well as on morphological changes in myoblasts, we asked
whether the lack of Glu MTs might also affect cell adhesion molecules
involved in myogenic morphogenesis or signaling of myogenic gene
expression. Integrins 7A and 1 form
transmembrane heterodimeric receptors that mediate association of the
extracellular matrix protein, laminin, to the intracellular actin
cytoskeleton in myotubes (38, 39). 7A integrin level
increases during skeletal muscle differentiation (40, 41), whereas
1A integrin level decreases as myoblasts switch to
expressing integrin 1D (42).
Accordingly, we examined expression of integrins 7A and
1A during differentiation of control and
NO2Tyr-treated L6 cells. Fig.
5 shows that, in control L6 cells,
7A integrin level increased dramatically as myoblasts
underwent differentiation ( 7A blot, C lanes);
conversely, 1A level decreased from high to undetectable during differentiation (Fig. 5, 1A blot, C
lanes) in agreement with Belkin et al. (42).
NO2Tyr-treated cells did not exhibit this integrin switch
(Fig. 5, NO2Tyr lanes): 7A
integrin was not abundant in NO2Tyr-treated cells at any
time from 0 to 10 days, with only a minor amount detected at 4 days. At
the same time, 1A level remained high at all stages
examined. Constitutive expression of integrin 1A was
previously reported to be sufficient to block the cell cycle withdrawal
requisite for myogenic differentiation in primary quail muscle cells
(43). In contrast, our NO2Tyr-treated L6 cells withdrew
from the cell cycle (i.e. they survived
-D-arabinofuranoside treatment) even though they
continued to express abundant integrin 1A. Myogenin
up-regulation has been correlated with up-regulation of integrin
7 (31, 44), and lack of myogenin activity in NO2Tyr-treated cells (Fig. 4) might contribute to their
failure to induce integrin 7. Thus, proper switching of
integrins was perturbed in post-mitotic L6 myoblasts in which Glu MT
formation was inhibited.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of cell surface adhesion molecules
in NO2Tyr-treated cells. Extracts of pH-shifted L6
cells without (control lanes, C) or with
NO2Tyr (NO2Tyr lanes) and
differentiated for 0-10 days were immunoblotted with antibodies to
integrin 1A, integrin 7A, and
-catenin. 65 µg of extract protein was loaded for integrin
detection, 60 µg for -catenin. Values were normalized by labeling
each blot with anti-Tyr tubulin antibody, as shown.
|
|
N-cadherin, a cell-cell adhesion molecule expressed in differentiating
skeletal muscle cells, forms cell surface clusters that are thought to
promote activation of myogenesis by helping align cells for fusion (45,
46). N-cadherin-dependent adhesion was reported to
up-regulate myogenin (47), and exogenously expressed N-cadherin was
shown to increase myogenesis and abundance of the N-cadherin binding
partner, -catenin, which functions in intracellular signaling (45).
Because inhibition of Glu MT formation by NO2Tyr prevented
myogenin up-regulation, we asked whether the inhibitor altered
-catenin level. However, the -catenin level increased ~2-fold
during myogenesis, and this increase was not affected by
NO2Tyr treatment (Fig. 5).
 |
DISCUSSION |
In this study, we tested the role of post-translational
detyrosination during myogenesis. Previous studies had been hampered by
the lack of direct inhibitors of TCP, which has not yet been purified
or cloned. In other systems, Glu MT function had been inhibited by
microinjecting anti-Glu antibodies (12, 14) or Glu tubulin protomers
(13), but neither approach was amenable to studies of myogenic cells. A
report by Eiserich et al. (17), that carboxypeptidase A
could not cleave NO2Tyr from tubulin in vitro,
suggested that TCP might possess similar substrate specificity. Our
demonstration that, indeed, NO2Tyr-MT substrate inhibits
TCP in vitro pointed to NO2Tyr-MTs as an
effective inhibitor of Glu MT formation in muscle cells. Successfully
obtaining enough NO2Tyr incorporation into MTs
to inhibit detyrosination effectively was predicated on the use of
a pH shift protocol that altered cells' Glu tubulin content reversibly.
The fact that Glu tubulin level was altered in response to
extracellular pH suggested that MT stability was also altered. Analysis
of acetylated tubulin and examination of MT behavior in vivo
by time-lapse microscopy corroborated this hypothesis (data not shown).
Although it is unclear how extracellular pH affects in vivo
MT stability, a putative mechanism is pH-induced changes in tubulin
polymerization. The effects we measured coincide with evidence from
other investigators that the quantity and, thus presumably, the
stability of MTs polymerized is exquisitely sensitive to pH in
vitro (48, 49) and in vivo (27). Instead of or in
addition to, pH could affect activity of stathmin/Op18, an
MT-destabilizer. For example, pH 6.8 enhances complexes of stathmin/Op18 with tubulin protomer, rather than with MT
protofilaments, favoring persistence of stable MTs. In contrast,
alkaline pH increases interaction of stathmin/Op18 with protofilaments,
thus destabilizing MTs (50-52). Future work will elucidate how
extracellular pH modifies MT dynamics; at present, we merely exploited
this phenomenon as a convenient means of optimizing
NO2Tyr incorporation.
NO2Tyr specifically inhibits detyrosination, as judged by
several criteria: First, the degree of NO2Tyr incorporation
into MTs, rather than the length of treatment or concentration of
NO2Tyr applied, predicted the severity of myogenic
inhibition. Furthermore, 2-nitro-p-cresyl, a nitrophenol
compound similar to NO2Tyr, neither affected myogenesis nor
became incorporated into tubulin, further supporting our conclusion
that NO2Tyr was effective only when incorporated into MTs
(see above). Third, NO2Tyr was detected only in tubulin,
suggesting that its incorporation was catalyzed only by the
tubulin-specific enzyme, TTL. Fourth, with or without NO2Tyr, MT acetylation occurred normally. Thus,
NO2Tyr administration inhibits only a single
post-translational modification, detyrosination.
Our data corroborated results of Khawaja et al. (7) and
Webster et al. (8), who showed that detyrosination is a
result of, rather than a contributor to, MT stabilization. The
specificity of NO2Tyr allowed us to test independently the
role of a single post-translational modification. Acetylation and
detyrosination occur along distinct but overlapping populations of
stable MTs (10, 11, 29), and both are up-regulated during myogenesis (16). Myogenesis was prevented when MT detyrosination was inhibited and
acetylation was unaffected; therefore, the two modifications are not
functionally redundant. No experiments to date address whether MT
acetylation is also required for myogenesis. That different post-translational modifications affect functions or localizations of
different MT subsets was suggested by Moreno and Schatten (53), who
showed that post-translationally glutamylated MTs (54) and acetylated
MTs were found in different compartments of developing spermatids.
Our finding that NO2Tyr treatment of L6 cells irreversibly
inhibited early myogenic events was not surprising, because the early
elaboration of Glu MTs had implicated them in events prior to fusion
(16). Our data showing early defects in cell elongation suggest that
inhibition of Glu MTs inhibits signaling required for myogenesis rather
than physically inhibiting fusion. Like myogenesis, early morphogenesis
during neurite outgrowth occurs concomitant with MT stabilization and
detyrosination (55, 56). Thus, by analogy, Glu MTs may be required for
neurite outgrowth, as well.
Our experiments demonstrate that Glu MTs are necessary for
myogenic differentiation. Other data, though, suggest that they may not
be sufficient. For example, although the MT-stabilizing drug, Taxol, increases Glu MT level (5), attempts to use low doses of
Taxol to re-induce myogenesis after NO2Tyr treatment were
unsuccessful (data not shown). Failure to rescue
NO2Tyr-treated cells implies that Glu MTs are not
sufficient for myogenic differentiation. Alternatively, the failure to
restart some events of myogenesis with other interdependent events
already in progress might have precluded differentiation that could
have otherwise been induced by Glu MTs.
NO2Tyr treatment of L6 myoblasts generated pleiotropic
effects upon differentiation. For example, NO2Tyr severely
compromised accumulation of active myogenin, which functions in early
myogenic transcription; this might lead to defects in protein
expression later in the myogenic time course. Although
NO2Tyr treatment had no discernible effect on the early
accumulation of muscle actin mRNA transcript, it prevented
accumulation of actin protein, along with myosin, another late myogenic
marker assembled into sarcomeres. A switch in integrins thought to
mediate cell adhesion changes was also prevented, in this case,
resulting from either a transcriptional or post-transcriptional block.
Taken together, our results suggest that Glu MTs play a critical
primary role early in the myogenic pathway and exert secondary effects
at later myogenic stages.
Previous studies have focused on signal transduction events leading to
the generation of Glu MTs (57, 58). In contrast, our data implicate a
signaling pathway that is activated by generation of Glu MTs;
failure of this signal perturbs myogenesis. Possible mechanisms
by which Glu MTs could signal their presence include changes in
motor activity, i.e. if Glu MTs change kinesin-based transport functions (59), or changes in binding of signal transduction molecules, i.e. if Glu MTs alter signaling to the nucleus.
In the latter scenario, if detyrosination were prevented, Glu
MT-binding molecules would fail to bind MTs, and changes in their
targeting and/or activity would result. Alternatively, without Glu MTs, molecules bound specifically to Tyr MTs might fail to dissociate from
MTs. The latter is unlikely, though, because the increase in Glu
subunits within the MTs is more dramatic than the decrease in Tyr subunits.
It is a formal possibility that the presence of NO2Tyr-MTs
may exacerbate the effects of inhibiting Glu MTs. Incorporation of a
novel residue, NO2Tyr, may structurally perturb binding of molecules that normally bind either to Glu- or Tyr-MTs but not to
NO2Tyr-MTs. This will be tested in future experiments.
Alternatively, NO2Tyr-tubulin could have downstream effects
by blocking further modification, i.e. removal of the
C-terminal residue of Glu tubulin to form 2-tubulin (54). The latter
possibility is unlikely, because 2-tubulin accumulates mainly in
neuronal MTs and has not been detected in muscle (60). In any case,
Western blots (Fig. 2), performed with equally reactive antibodies (not
shown) document that NO2Tyr treatment resulted in a Glu-MT
decrease that was more significant than the
NO2Tyr-MT increase. This is probably because, as
shown in vitro in TCP assays, NO2Tyr-MTs bind
tightly to TCP and prevent its subsequent activity to detyrosinate Tyr subunits. Even if a minuscule amount of NO2Tyr-MTs is
somehow responsible for potently affecting myogenic MTs, our work shows that changing the C-terminal residue from Glu to NO2Tyr, or
to Tyr, abrogates functions required for myogenesis.
Our data suggest the existence of Glu MT-binding molecules; candidates
for these include proteins that show muscle-specific expression and/or
specific interaction with stable MTs. An interesting candidate is MURF,
a muscle-specific RING-finger protein required for myoblast
differentiation, which has been shown to interact with stable MTs (61).
Involvement of MURF in transcription may provide an important link
between MT properties and myogenic gene expression. Other proteins such
as CLASPS, APC, and EB1, whose expression is not limited to muscle,
bind to MTs stabilized by plus-end capping (62-64). Plus-end binding
species may exert MT-stabilizing effects early in the myogenic pathway,
possibly upstream of MT detyrosination. These may be distinct from Glu
MT-binding molecules that signal the stabilization of certain MTs.
Future studies will be needed to identify mechanisms by which Glu MTs
function in the signaling of myogenic events.
 |
ACKNOWLEDGEMENTS |
Many investigators generously contributed
reagents important to the work. We also thank Drs. Judith Venuti and
Ron Breslow for invigorating discussions, Drs. Ying Sung and Aleksandar
Micevski for technical assistance, and Jóhanna
Àrnadóttir for critical reading of the manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant HL 62617 (to J. C. B.) and traineeships T32 GM 08224 and T32 CA
09503 (to W. C.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: MC2450, 804 Sherman
Fairchild Center, Columbia University, 1212 Amsterdam Ave., New York,
NY 10027-2450. Tel.: 212-854-5570; Fax: 212-854-0773; E-mail:
jcb4@columbia.edu.
Published, JBC Papers in Press, June 17, 2002, DOI 10.1074/jbc.M204930200
 |
ABBREVIATIONS |
The abbreviations used are:
MT, microtubule;
TCP, tubulin-specific carboxypeptidase;
TTL, tubulin tyrosine ligase;
Tyr, tyrosinated;
DMEM, Dulbecco's modified Eagle's medium;
NO2Tyr, 3-nitrotyrosine;
MOPS, 4-morpholinepropanesulfonic
acid.
 |
REFERENCES |
| 1.
|
Walczak, C. E.
(2000)
Curr. Opin. Cell Biol.
12,
52-56[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Ludueña, R. F.
(1998)
Int. Rev. Cytol.
178,
207-275[Medline]
[Order article via Infotrieve]
|
| 3.
|
Bulinski, J. C.,
and Gundersen, G. G.
(1991)
Bioessays
13,
285-293[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Bré, M. H.,
Kreis, T. E.,
and Karsenti, E.
(1987)
J. Cell Biol.
105,
1283-1296[Abstract/Free Full Text]
|
| 5.
|
Gundersen, G. G.,
Khawaja, S.,
and Bulinski, J. C.
(1987)
J. Cell Biol.
105,
251-264[Abstract/Free Full Text]
|
| 6.
|
Webster, D. R.,
Gundersen, G. G.,
Bulinski, J. C.,
and Borisy, G. G.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
9040-9044[Abstract/Free Full Text]
|
| 7.
|
Khawaja, S.,
Gundersen, G. G.,
and Bulinski, J. C.
(1988)
J. Cell Biol.
106,
141-149[Abstract/Free Full Text]
|
| 8.
|
Webster, D. R.,
Wehland, J.,
Weber, K.,
and Borisy, G. G.
(1990)
J. Cell Biol.
111,
113-122[Abstract/Free Full Text]
|
| 9.
|
Gundersen, G. G.,
Kalnoski, M. H.,
and Bulinski, J. C.
(1984)
Cell
38,
779-789[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Schulze, E.,
Asai, D. J.,
Bulinski, J. C.,
and Kirschner, M.
(1987)
J. Cell Biol.
105,
2167-2177[Abstract/Free Full Text]
|
| 11.
|
Bulinski, J. C.,
Richards, J. E.,
and Piperno, G.
(1988)
J. Cell Biol.
106,
1213-1220[Abstract/Free Full Text]
|
| 12.
|
Gurland, G.,
and Gundersen, G. G.
(1995)
J. Cell Biol.
131,
1275-1290[Abstract/Free Full Text]
|
| 13.
|
Kreitzer, G.,
Liao, G.,
and Gundersen, G. G.
(1999)
Mol. Biol. Cell
10,
1105-1118[Abstract/Free Full Text]
|
| 14.
|
Lin, S. X.,
Gundersen, G. G.,
and Maxfield, F. R.
(2002)
Mol. Biol. Cell
13,
96-109[Abstract/Free Full Text]
|
| 15.
|
Kirschner, M.,
and Mitchison, T.
(1986)
Cell
45,
329-342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Gundersen, G. G.,
Khawaja, S.,
and Bulinski, J. C.
(1989)
J. Cell Biol.
109,
2275-2288[Abstract/Free Full Text]
|
| 17.
|
Eiserich, J. P.,
Estevez, A. G.,
Bamberg, T. V., Ye, Y. Z.,
Chumley, P. H.,
Beckman, J. S.,
and Freeman, B. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
6365-6375[Abstract/Free Full Text]
|
| 18.
|
Eiserich, J. P.,
Hristova, M.,
Cross, C. E.,
Jones, A. D.,
Freeman, B. A.,
Halliwell, B.,
and van der Vliet, A.
(1998)
Nature
391,
393-397[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
van der Vliet, A.,
Eiserich, J. P.,
Shigenaga, M. K.,
and Cross, C. E.
(1999)
Am. J. Respir. Crit. Care Med.
160,
1-9[Free Full Text]
|
| 20.
|
Ischiropoulos, H.
(1998)
Arch. Biochem. Biophys.
356,
1-11[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Kalisz, H. M.,
Erck, C.,
Plessmann, U.,
and Wehland, J.
(2000)
Biochim. Biophys. Acta
1481,
1131-1138
|
| 22.
|
Chiu, C. P.,
and Blau, H. M.
(1984)
Cell
37,
879-887[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Chapin, S. J.,
and Bulinski, J. C.
(1991)
Methods Enzymol.
196,
254-264[Medline]
[Order article via Infotrieve]
|
| 24.
|
Gruber, D.,
Faire, K.,
and Bulinski, J. C.
(2001)
Cell Motil. Cytoskel.
49,
115-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Webster, D. R.,
Modesti, N. M.,
and Bulinski, J. C.
(1992)
Biochemistry
31,
5849-5856[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Webster, D. R.,
and Oxford, M. G.
(1996)
J. Cell. Biochem.
60,
424-436[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Watanabe, K.,
Hamaguchi, M. S.,
and Hamaguchi, Y.
(1997)
Cell Motil. Cytoskel.
37,
263-270[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Shiraishi, F.,
Shimizu, F.,
and Kubota, K.
(1978)
Kokuritsu Kogai Kenkyusho Kenkyu Hokoku.
5,
77-95
|
| 29.
|
Piperno, G.,
LeDizet, M.,
and Chang, X.
(1987)
J. Cell Biol.
104,
289-302[Abstract/Free Full Text]
|
| 30.
|
Bulinski, J. C.,
Kumar, S.,
Titani, K.,
and Hauschka, S. D.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
1506-1510[Abstract/Free Full Text]
|
| 31.
|
Haider, S. R.,
Wang, W.,
and Kaufman, S. J.
(1994)
Exp. Cell Res.
210,
278-286[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Braun, T.,
Bober, E.,
Buschlausen-Denker, G.,
Kotz, S.,
Grzeschik, K. H.,
and Arnold, H. H.
(1989)
EMBO J.
8,
3617-3625[Medline]
[Order article via Infotrieve]
|
| 33.
|
Wright, W. E.,
Sassoon, D. A.,
and Lin, V. K.
(1989)
Cell
56,
607-617[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Li, L.,
Zhou, J.,
James, G.,
Harrison, R. H.,
Czech, M. P.,
and Olson, E. N.
(1992)
Cell
71,
1181-1194[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Brennan, T. J.,
and Olson, E. N.
(1990)
Genes Dev.
4,
582-595[Abstract/Free Full Text]
|
| 36.
|
Hashimoto, N.,
Ogashiwa, M.,
Okumura, E.,
Endo, T.,
Iwashita, S.,
and Kishimoto, T.
(1994)
FEBS Lett.
352,
236-242[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Tedesco, D.,
Caruso, M.,
Fantuzzi, L. F.,
and Vesco, C.
(1995)
J. Virol.
69,
6947-6957[Abstract]
|
| 38.
|
Juliano, R. L.,
and Haskill, S.
(1993)
J. Cell Biol.
120,
577-585[Free Full Text]
|
| 39.
|
Clark, E. A.,
and Brugge, J. S.
(1995)
Science
268,
233-239[Abstract/Free Full Text]
|
| 40.
|
Kaufman, S. J.,
Foster, R. F.,
Haye, K. R.,
and Faiman, L. E.
(1985)
J. Cell Biol.
100,
1977-1987[Abstract/Free Full Text]
|
| 41.
|
Song, W. K.,
Wang, W.,
Foster, R. F.,
Bielser, D. A.,
and Kaufman, S. J.
(1992)
J. Cell Biol.
117,
643-657[Abstract/Free Full Text]
|
| 42.
|
Belkin, A. M.,
Zhidkova, N. I.,
Balzac, F.,
Altruda, F.,
Tomatis, D.,
Maier, A.,
Tarone, G.,
Koteliansky, V. E.,
and Burridge, K.
(1996)
J. Cell Biol.
132,
211-226[Abstract/Free Full Text]
|
| 43.
|
Sastry, S. K.,
Lakonishok, M., Wu, S.,
Truong, T. Q.,
Huttenlocher, A.,
Turner, C. E.,
and Horwitz, A. F.
(1999)
J. Cell Biol.
144,
1295-1309[Abstract/Free Full Text]
|
| 44.
|
Ziober, B. L.,
and Kramer, R. H.
(1996)
J. Biol. Chem.
271,
22915-22922[Abstract/Free Full Text]
|
| 45.
|
Redfield, A.,
Nieman, M. T.,
and Knudsen, K. A.
(1997)
J. Cell Biol.
138,
1323-1331[Abstract/Free Full Text]
|
| 46.
|
Goichberg, P.,
and Geiger, B.
(1998)
Mol. Biol. Cell
9,
3119-3131[Abstract/Free Full Text]
|
| 47.
|
Seghatoleslami, M. R.,
Myers, L.,
and Knudsen, K. A.
(2000)
J. Cell. Biochem.
77,
252-264[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Olmsted, J. B.,
and Borisy, G. G.
(1975)
Biochemistry
14,
2996-3005[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Galella, G.,
and Smith, D. B.
(1979)
Can. J. Biochem.
57,
1368-1375[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Curmi, P. A.,
Andersen, S. S.,
Lachkar, S.,
Gavet, O.,
Karsenti, E.,
Knossow, M.,
and Sobel, A.
(1997)
J. Biol. Chem.
272,
25029-25036[Abstract/Free Full Text]
|
| 51.
|
Larsson, N.,
Segerman, B.,
Howell, B.,
Fridell, K.,
Cassimeris, L.,
and Gullberg, M.
(1999)
J. Cell Biol.
146,
1289-1302[Abstract/Free Full Text]
|
| 52.
|
Andersen, S. S. L.
(2000)
Trends Cell Biol.
10,
261-267[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Moreno, R. D.,
and Schatten, G.
(2000)
Cell Motil. Cytoskel.
46,
235-246[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Eddé, B.,
Rossier, J., Le,
Caer, J. P.,
Desbruyeres, E.,
Gros, F.,
and Denoulet, P.
(1990)
Science
247,
83-85[Abstract/Free Full Text]
|
| 55.
|
Wehland, J.,
and Weber, K.
(1987)
J. Cell Sci.
88,
185-203[Abstract/Free Full Text]
|
| 56.
|
Baas, P. W.,
and Black, M. M.
(1990)
J. Cell Biol.
111,
495-509[Abstract/Free Full Text]
|
| 57.
|
Cook, T. A.,
Nagasaki, T.,
and Gundersen, G. G.
(1998)
J. Cell Biol.
141,
175-185[Abstract/Free Full Text]
|
| 58.
|
Palazzo, A. F.,
Cook, T. A.,
Alberts, A. S.,
and Gundersen, G. G.
(2001)
Nat. Cell Biol.
3,
723-729[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Lafanechère, L.,
and Job, D.
(2000)
Neurochem. Res.
25,
11-18[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Liao, G.,
and Gundersen, G. G.
(1998)
J. Biol. Chem.
273,
9797-9803[Abstract/Free Full Text]
|
| 61.
|
Spencer, J. A.,
Eliazer, S.,
Ilaria, R. L.,
Richardson, J. A.,
and Olson, E. N.
(2000)
J. Cell Biol.
150,
771-784[Abstract/Free Full Text]
|
| 62.
|
Akhmanova, A.,
Hoogenraad, C. C.,
Drabek, K.,
Stepanova, T.,
Dortland, B.,
Verkerk, T.,
Vermeulen, W.,
Burgering, B. M.,
Dez Eeuw, C. I.,
Growveld, F.,
and Galjart, N.
(2001)
Cell.
104,
923-935[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Mimori-Kiyosue, Y.,
Shiina, N.,
and Tsukita, S.
(2000)
J. Cell Biol.
148,
505-517[Abstract/Free Full Text]
|
| 64.
|
Morrison, E. E.,
Wardleworth, B. N.,
Askham, J. M.,
Markham, A. F.,
and Meredith, D. M.
(1998)
Oncogene
17,
3471-3477[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Zhang, K. J. M. Zaal, J. Sheridan, A. Mehta, G. G. Gundersen, and E. Ralston
Microtubule plus-end binding protein EB1 is necessary for muscle cell differentiation, elongation and fusion
J. Cell Sci.,
May 1, 2009;
122(9):
1401 - 1409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ye, C. Quijano, K. M. Robinson, K. C. Ricart, A. L. Strayer, M. A. Sahawneh, J. J. Shacka, M. Kirk, S. Barnes, M. A. Accavitti-Loper, et al.
Prevention of Peroxynitrite-induced Apoptosis of Motor Neurons and PC12 Cells by Tyrosine-containing Peptides
J. Biol. Chem.,
March 2, 2007;
282(9):
6324 - 6337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev,
January 1, 2007;
87(1):
315 - 424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Blanchard-Fillion, D. Prou, M. Polydoro, D. Spielberg, E. Tsika, Z. Wang, S. L. Hazen, M. Koval, S. Przedborski, and H. Ischiropoulos
Metabolism of 3-nitrotyrosine induces apoptotic death in dopaminergic cells.
J. Neurosci.,
June 7, 2006;
26(23):
6124 - 6130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kasina, W. Rizwani, K. V. N. Radhika, and S. S. Singh
Nitration of Profilin Effects Its Interaction with Poly (L-Proline) and Actin
J. Biochem.,
December 1, 2005;
138(6):
687 - 695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Destaing, F. Saltel, B. Gilquin, A. Chabadel, S. Khochbin, S. Ory, and P. Jurdic
A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts
J. Cell Sci.,
July 1, 2005;
118(13):
2901 - 2911.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-C. T. Huang, Z. Li, L. E. Brighton, J. L. Carson, S. Becker, and J. M. Soukup
3-Nitrotyrosine attenuates respiratory syncytial virus infection in human bronchial epithelial cell line
Am J Physiol Lung Cell Mol Physiol,
May 1, 2005;
288(5):
L988 - L996.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. McElhinny, C. N. Perry, C. C. Witt, S. Labeit, and C. C. Gregorio
Muscle-specific RING finger-2 (MURF-2) is important for microtubule, intermediate filament and sarcomeric M-line maintenance in striated muscle development
J. Cell Sci.,
July 1, 2004;
117(15):
3175 - 3188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Finkelstein, W. Chang, P.-H. G. Chao, D. Gruber, A. Minden, C. T. Hung, and J. C. Bulinski
Roles of microtubules, cell polarity and adhesion in electric-field-mediated motility of 3T3 fibroblasts
J. Cell Sci.,
March 15, 2004;
117(8):
1533 - 1545.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|